Diarrheal disease remains a significant public health challenge globally, with over 1 million deaths occurring each year, nearly half affecting children under age 5. Shigellosis, caused by Shigella bacteria, represents one of the leading bacterial causes of these deaths and is spread through contaminated food and water, with cases more prevalent in areas lacking adequate sanitation. The disease causes prolonged diarrhea, malnutrition, and potential cognitive impairment in survivors, with peak risk occurring between 12 and 23 months of age.
A vaccine candidate designated WRSs2, developed by the Walter Reed Army Institute of Research, demonstrated 89% effectiveness in preventing shigellosis according to results published in The Lancet Infectious Diseases this summer. The trial involved 108 adults, with half receiving a weakened version of the Shigella bacteria suspended in liquid administered twice, one month apart, while the other half received salt water. In the placebo group, 81% of participants became ill with diarrhea and fever after deliberate exposure to the bacteria. Researchers noted that the 89% efficacy figure represents the highest effectiveness ever achieved against Shigella, surpassing previous vaccine candidates that reached maximum efficacy rates of 74%, 40%, and 28% respectively.
The vaccine was not without side effects, with over half of recipients reporting headaches and approximately 45% experiencing diarrhea following vaccination. However, no participants required hospitalization due to vaccine-related complications. Researchers characterized the safety profile as acceptable while indicating that further refinement of the vaccine’s safety-efficacy balance would continue.
Experts emphasize that the next critical step involves testing the vaccine in children, particularly those under age 5 in regions with high rates of diarrheal disease and poor sanitation, since this population bears the greatest burden of mortality and morbidity from shigellosis. Rising antimicrobial resistance has complicated treatment options, with some regions reporting resistance exceeding 80% for certain antibiotics, making a vaccine increasingly important. Researchers are considering development of combination vaccines protecting against multiple bacterial causes of diarrheal disease, though practical challenges regarding implementation timeline remain under discussion.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI